These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9863499)

  • 1. Combinations of three or four HIV virostatics applied in short sequences which differ from each other by drug rotation. Preliminary results of the viral loads and CD4 numbers.
    Mathé G; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1997; 51(10):417-26. PubMed ID: 9863499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothetical reasons of the HIV1-AIDS "tritherapy" failure. A challenging model.
    Mathé G
    Biomed Pharmacother; 1997; 51(10):413-6. PubMed ID: 9863498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation.
    Mathe G; Morette C; Hallard M; Pontiggia P; Blanquet D; Hage F
    Acta Pharmacol Sin; 2002 Jan; 23(1):1-15. PubMed ID: 11860730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinations of four virostatics applied in rotational sequences induce an exponential VL regression curve, the first part of which is rapidly decreasing to a PCR-undetectable level, while the last part is insensitive to the model. Indications for virostatic and immunotherapeutic reinforcements?
    Mathé G
    Biomed Pharmacother; 1999 Mar; 53(2):57-62. PubMed ID: 10337459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combinations with other HIV1 virostatics.
    Mathé G; Triana K; Pontiggia P; Blanquet D; Hallard M; Morette C
    Biomed Pharmacother; 1998; 52(9):391-6. PubMed ID: 9856286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The failure of HAART to cure the HIV-1/AIDS complex. Suggestions to add integrase inhibitors as complementary virostatics, and to replace their continuous long combination applications by short sequences differing by drug rotations.
    Mathé G
    Biomed Pharmacother; 2001 Jul; 55(6):295-300. PubMed ID: 11478579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will killing the last HIV1 particle cure AIDS patients? II: Second Part. Decrease of viral load and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after the use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy?
    Mathé G; Colasanté U; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(10):473-9. PubMed ID: 9091060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kinetics of cancer cells and of HIV1: the problems of cell and virus rebounds and of latency.
    Mathé G
    Biomed Pharmacother; 1998; 52(10):413-20. PubMed ID: 9921409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo eradication of Friend virus as an experimental HIV-model, by combination of zidovudine, acriflavine and an ellipticine analogue. Possible application to the treatment of human pre-AIDS?
    Mathé G; Pontiggia P; Bourut C; Chenu E; Orbach-Arbouys S
    Biomed Pharmacother; 1994; 48(2):51-3. PubMed ID: 7919105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Virostatics" as a potential new class of HIV drugs.
    Kelly LM; Lisziewicz J; Lori F
    Curr Pharm Des; 2004; 10(32):4103-20. PubMed ID: 15579091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can virostatic chemotherapy and/or adoptive allogeneic immunotherapy eradicate in vivo Friend's virus infection?
    Mathé G; Trabaud M; Chenu E; Bourut C
    Biomed Pharmacother; 1990; 44(1):57-9. PubMed ID: 1369695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will killing the last HIV1 particle cure AIDS patients? Doesn't CMV activation and/or a graft-versus-host component of the disease, also have to be considered? I. First of two parts.
    Mathé G
    Biomed Pharmacother; 1996; 50(5):185-206. PubMed ID: 8949400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
    Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
    AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.
    Baxter JD; Mayers DL; Wentworth DN; Neaton JD; Hoover ML; Winters MA; Mannheimer SB; Thompson MA; Abrams DI; Brizz BJ; Ioannidis JP; Merigan TC
    AIDS; 2000 Jun; 14(9):F83-93. PubMed ID: 10894268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virostatic in vivo effect of elliptinium on Friend's retrovirus (a model for HIV infection).
    Mathé G; Chenu E; Bourut C
    Biomed Pharmacother; 1990; 44(1):1-3. PubMed ID: 1369686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy for HIV-2 infected patients.
    Smith NA; Shaw T; Berry N; Vella C; Okorafor L; Taylor D; Ainsworth J; Choudhury A; Daniels RS; El-Gadi S; Fakoya A; Moyle G; Oxford J; Tedder R; O'Shea S; de Ruiter A; Breuer J
    J Infect; 2001 Feb; 42(2):126-33. PubMed ID: 11531319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.